Veru is trading 6.1% lower at $2.29 amid broader market pressure. - The S&P 500 is down 1.16%, while the Nasdaq is down 2.08%. - Biotech stocks are weaker, with XBI down 2.06%. - No clear Veru-specific negative catalyst was identified for October 16. Oppenheimer’s reiterated bullish rating and $24 price target were reported earlier, ahead of the obesity-trial data, not as adverse news today.